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Familial Mediterranean fever (FMF) is a recessively inherited disorder predisposing to renal amyloidosis and associated
with mutations in MEFV, a gene encoding a protein of unknown function. Differences in clinical expression have
been attributed to MEFV-allelic heterogeneity, with the M694V/M694V genotype associated with a high prevalence
of renal amyloidosis. However, the variable risk for patients with identical MEFV mutations to develop this severe
complication, prevented by lifelong administration of colchicine, strongly suggests a role for other genetic and/or
environmental factors. To overcome the well-known difficulties in the identification of modifying genetic factors, we
investigated a relatively homogeneous population sample consisting of 137 Armenian patients with FMF from 127
independent families living in Armenia. We selected the SAA1, SAA2, and APOE genes—encoding serum amyloid
proteins and apolipoprotein E, respectively—as well as the patients’ sex, as candidate modifiers for renal amyloidosis.
A stepwise logistic-regression analysis showed that the SAA1a/a genotype was associated with a sevenfold increased
risk for renal amyloidosis, compared with other SAA1 genotypes (odds ratio [OR] 6.9; 95% confidence interval [CI]
2.5–19.0). This association, which was present whatever the MEFV genotype, was extremely marked in patients
homozygous for M694V (11/11). The risk for male patients of developing renal amyloidosis was fourfold higher
than that for female patients ( ; 95% ). This association, particularly marked in patients whoORp 4.0 CIp 1.5–10.8
were not homozygous for M694V (34.0% vs. 11.6%), was independent of SAA1-allelic variations. Polymorphisms
in the SAA2 or APOE gene did not appear to influence susceptibility to renal amyloidosis. Overall, these data, which
provide new insights into the pathophysiology of FMF, demonstrate that susceptibility to renal amyloidosis in this
Mendelian disorder is influenced by at least two MEFV-independent factors of genetic origin—SAA1 and sex—that
act independently of each other.
Introduction
Mutations in pyrin/marenostrin, a protein of unknown
function, have been identified in patients with familial
Mediterranean fever (FMF [MIM 249100]) (French
FMF Consortium 1997; International FMF Consortium
1997; Bernot et al. 1998; Booth et al. 1998b; Cazeneuve
et al. 1999), an autosomal recessive condition particu-
larly common in several populations of Mediterranean
extraction (Sohar et al. 1967), in which the prevalence
reaches as high as 1/200 individuals. This disease is char-
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acterized by a marked variability in clinical expression
between and within families (Sohar et al. 1967), a phe-
notypic feature that, combined with the absence of pa-
thognomonic clinical and biological signs, makes the di-
agnosis of FMF difficult to establish. This diagnosis is
indeed based on the occurrence of recurrent episodes of
fever and serosal inflammation, usually revealed by ster-
ile peritonitis, arthritis, and/or pleurisy, which may lead
to unnecessary invasive investigations. However, thema-
jor concern in FMF is the risk of amyloidosis, mainly
renal, which, in the absence of daily and lifelong ad-
ministration of colchicine (Zemer et al. 1986), develops
over years and progresses to renal failure.
The identification of the gene responsible for FMF
(designated “MEFV”) (French FMF Consortium 1997;
International FMF Consortium 1997) has opened up
new ways to manage the disease—especially by provid-
ing the first objective test of diagnostic value (Cazeneuve
et al. 1999)—and to decipher the pathophysiology of
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this disorder. The first genotype-phenotype correlation
studies showed that the M694V homozygous genotype
was associated with a more severe form of the disease,
as judged by an earlier age at onset, a higher prevalence
of pleurisy (Dewalle et al. 1998), a higher frequency of
arthritis (Dewalle et al. 1998; Cazeneuve et al. 1999),
and, most importantly, in patients who did not have
access to a regular colchicine therapy, a higher preva-
lence of renal amyloidosis (Cazeneuve et al. 1999; Sho-
hat et al. 1999). However, it should be emphasized that
this latter observation was assessed at the population
level, whereas, at the individual level, it is well estab-
lished that not all patients with theM694V homozygous
genotype develop renal amyloidosis (Cazeneuve et al.
1999; Shohat et al. 1999), and, conversely, not all the
patients with FMF who have renal amyloidosis carry
the M694V homozygous genotype (Yalcinkaya et al.
1998; Cazeneuve et al. 1999; Shohat et al. 1999). Taken
together, these observations strongly suggest that the
MEFV gene does not account for the total genetic con-
tribution to renal amyloidosis susceptibility and that as-
yet-unknown modifying factors may have a protective
or deteriorating effect on renal function. The identifi-
cation of these factors would thus be of critical impor-
tance in both improving the accuracy of renal amyloi-
dosis–risk prediction in individual patients and ex-
tending our understanding of the pathophysiology of
this major complication of the disease.
To investigate the mechanisms underlying such a var-
iability in the risk for patients with FMF to develop renal
amyloidosis, we have examined potential risk factors in
a large cohort of independent Armenian patients living
in Armenia; in this relatively homogeneous population
sample, the complexity of genetic and environmental fac-
tors contributing to renal amyloidosis susceptibility is
indeed expected to be minimal. We considered the ge-
notype at the SAA1, SAA2, and APOE loci, as well as
the patients’ sex, as good candidate modifier factors for
this severe complication. Indeed, the amyloid A1 (AA1)
and A2 (AA2) proteins, which result from proteolytic
cleavage of the serum amyloid A1 (SAA1) andA2 (SAA2)
proteins, are major protein components of the amyloid
A deposits found in secondary amyloidosis (Liepnieks et
al. 1995); the apolipoprotein E4 (APOE4) allele is a
well-known risk factor for both the late-onset familial
and the sporadic forms of Alzheimer disease, two con-
ditions characterized by brain deposition of the b-amy-
loid protein (Saunders et al. 1993). We also examined
the influence of sex on renal amyloidosis, given the un-
balanced sex ratio documented in nearly all FMF pop-
ulation samples studied so far (Wolff 1994). Finally, to
overcome the confounding effect of the M694V homo-
zygous genotype on the possible association of each stud-
ied variable with renal amyloidosis, we also took into
account the MEFV genotype.
Patients and Methods
Patients
We investigated 137 patients with FMF (age 3–99
years, mean 27.7 years; male:female ratio 1.40) from
127 unrelated families living in Armenia. Clinical fea-
tures were recorded through a standardized form, and
the diagnosis of FMF was made according to established
clinical criteria (Livneh et al. 1997). The duration of the
disease represents the delay between the onset of clinical
signs and the time of this study; these data were available
in 129/137 patients. Forty-seven individuals presented
with renal amyloidosis, as diagnosed by persistent pro-
teinuria during childhood or early adulthood of patients
with FMF (Zemer et al. 1986), and/or nephrotic syn-
drome or chronic renal failure. Since the aim of this study
was to evaluate the impact of several factors on the
occurrence of renal amyloidosis, we oriented our re-
cruitment toward patients presenting with this compli-
cation, thereby explaining the overall higher percentage
(47/137 [34%]) of Armenian patients with FMF pre-
senting with renal amyloidosis than has been reported
elsewhere (Meyerhoff 1980; Cazeneuve et al. 1999). Be-
cause colchicine was not easily available in Armenia,
patients could not have access to daily administration
of colchicine until 1998 or 1999. Informed consent was
obtained from all patients or their parents.
Molecular Genetic Analyses
MEFV Mutation Detection.—Genomic DNA was iso-
lated, using standard procedures, from peripheral leu-
kocytes. Themutation analysis was performed according
to Cazeneuve et al. (1999). In brief, we searched for the
M694V and V726A mutations by means of restriction-
enzyme analyses performed on PCR products spanning
these sites. In patients carrying, at most, only one of
these twomutations, we completed theMEFV gene anal-
ysis by screening all 10 coding exons and their flanking
intronic sequences for mutations, using denaturing gra-
dient gel electrophoresis. Samples displaying a shift in
mobility were subsequently directly sequenced.
Analysis of Polymorphisms in Candidate Modifying
Genes.—The SAA1a, SAA1b, and SAA1g isoforms are
encoded by the V52-A57, A52-V57, and A52-A57 SAA1
alleles, respectively. The SAA2a and SAA2b isoforms are
encoded by the H71 and R71 SAA2 alleles, respectively.
We searched for the A/V52 and A/V57 polymorphisms
of the SAA1 gene and the H/R71 polymorphism of the
SAA2 gene by restriction-enzyme analysis of the PCR
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Table 1
Genotypes of the Patients at the MEFV, SAA1, SAA2, and APOE Loci, According to the Presence or Absence of Renal Amyloidosis
(Univariate Analysis)
PATIENTS
NO. (%) OF PATIENTS WITH GENOTYPE
MEFV SAA1 SAA2 APOE
M694V/
M694V Othera P a/a Otherb P a/a Otherc P 3/4 Otherd P
With RA 24 (51.1) 23 (48.9) 22 (46.8) 25 (53.2) 35 (74.5) 12 (25.5) 5 (10.6) 42 (89.4)
Without RA 17 (18.9) 73 (81.1) 15 (16.7) 75 (83.3) 56 (62.2) 34 (37.8) 13 (14.4) 77 (85.6)
Overall .0001 .0002 .150 .530
NOTE.—RA p renal amyloidosis.
a M694V/V726A, M694V/M680I, and M680I/V726A genotypes were the most frequent other genotypes, carried by 8, 5, and 2 patients
with RA and by 23, 10, and 8 patients without RA, respectively.
b a/g, b/g, g/g, a/b, and b/b genotypes were carried by 2, 1, 1, 12, and 9 patients with RA and by 1, 2, 0, 38, and 34 patients without RA,
respectively.
c b/b and a/b genotypes were carried by 2 and 10 patients with RA and by 0 and 34 patients without RA, respectively.
d 2/2, 2/3, and 3/3 genotypes were carried by 0, 4 , and 38 patients with RA, and by 1, 9, and 67 patients without RA, respectively.
fragments spanning these sites, as described elsewhere
(Moriguchi et al. 1999).
The 2, 3, and 4 ApoE isoforms are encoded by the
C112-C158, C112-R158, and R112-R158 APOE al-
leles, respectively. The R/C112 and R/C158 polymor-
phisms of the APOE gene were studied by restriction-
enzyme analysis, as follows: the genotype at position 112
was determined by FspI restriction analysis of a 147-bp
PCR product generated with primers Apo112-f (5′-GA-
AGGCCTACAAATCGGAAC-3′) and Apo112-r (5′-CC-
GCGGTACTGCACCAGGCGGCTG-3′ [this oligonu-
cleotide is a mismatched primer designed to create an
FspI restriction site in the presence of the R112 allele]);
the genotype at position 158 was determined by HaeII
restriction analysis of a 272-bp PCR product generated
with primers Apo158-f (5′-CGGCGAGGTGCAGGC-
CATGC-3′) and Apo158-r (5′-AGGCCTGGGCCCGC-
TCCTGT-3′). Restriction fragments were separated on
a 2% agarose gel.
Statistical Analyses
In univariate analyses, factors associated with the pres-
ence of renal amyloidosis were tested using the x2 test (or
Fisher’s exact test when appropriate) for categorical data
and one-way ANOVA test (or Mann-Whitney nonpara-
metric test when appropriate) for quantitative data. To
avoid the confounding effect of the M694V homozygous
genotype, which is strongly related to renal amyloidosis,
we subsequently tested the factors potentially related to
renal amyloidosis after adjustment on the MEFV geno-
type, using the Mantel-Haenszel test and a two-way
ANOVA test for categorical data and quantitative data,
respectively. Finally, to point out factors independently
associated with renal amyloidosis, we performed a mul-
tivariate analysis bymeans of a stepwise logistic regression
analysis, allowing factors with in the univariateP  .10
analysis to enter themodel. Factorswith in logisticP ! .05
regression were kept in the model. We also tested first-
degree interaction between the patients’ sex and the ge-
notype at the SAA1 locus. The interaction between the
genotype at the MEFV locus and the genotype at the
SAA1 locus was not tested, since a cell equal to 0 made
the estimation of the coefficient impossible.
Results
The study cohort, consisting of 137 patients with FMF,
was divided into two groups, according to the presence
( ) or absence ( ) of renal amyloidosis atnp 47 np 90
study entry. These two groups of patients (mean age
or years, respectively;27.4 13.5 27.8 16.2 Pp
) were subsequently compared with each other with.806
respect to the following variables: the genotype at the
MEFV, SAA1, SAA2, and APOE loci, the patients’ sex,
the duration of the disease, and the age at onset.
Genotypes at the MEFV, SAA1, SAA2, and APOE Loci
and Renal Amyloidosis
Table 1 summarizes the relationship between the geno-
types at the MEFV and candidate modifier loci and the
presence or absence of renal amyloidosis, as assessed by
means of univariate analyses:
MEFV.—The frequency of the M694V homozygous
genotype in the group of patients with renal amyloidosis
(51.1%) was significantly higher than that observed in
the group of patients without renal amyloidosis (18.9%,
). In contrast, there was no significant differ-Pp .0001
ence in the frequency of the other most commonMEFV
genotypes (i.e., M694V/V726A, M694V/M680I, and
M680I/V726A) between the two groups of patients
(data not shown).
SAA1.—As shown in table 1, the frequency of renal
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Figure 1 Influence of the genotype at the SAA1 locus (a) and
of sex (b) on the risk of developing renal amyloidosis, according to
MEFV genotypes (Mantel-Haenszel test).
amyloidosis in the group of patients carrying the SAA1a/
a genotype was higher than that observed in patients
carrying another SAA1 genotype ( ). This dif-Pp .0002
ference persisted when adjusted on the MEFV genotype
(fig. 1a; ) and was extremely marked in pa-Pp .0001
tients with the M694V homozygous genotype; it is in-
deed noteworthy that, in this latter group, all the patients
who carried the SAA1a/a genotype (11/11) presented
with renal amyloidosis. In contrast, whatever the ge-
notype at the MEFV locus, the frequency of renal amy-
loidosis among patients carrying only one SAA1a allele
and among those who did not carry any SAA1a allele
did not differ statistically—that is, M694V homozygous
genotype, 43.7% versus 42.9%; non-M694V homozy-
gous genotypes, 18.9% versus 15.2% (data not shown).
SAA2.—The frequency of renal amyloidosis was not
significantly different in patients carrying the SAA2a/a
genotype, compared with those with other SAA2 geno-
types ( ; table 1). Similar results were obtainedPp .150
after adjustment on the MEFV genotype (M694V ho-
mozygous genotype: 66.7% vs. 42.9%; non-M694V ho-
mozygous genotypes: 26.7% vs. 18.7%; Mantel-Haen-
szel test: ; data not shown).Pp .178
APOE.—There was no difference in the frequency of
renal amyloidosis between the group of patients carrying
at least one APOE4 allele (i.e., 3/4 genotype in our
cohort of patients) and the groups of patients carrying
another APOE genotype ( ; table 1). SimilarPp .530
results were obtained after adjustment on the MEFV
genotype (M694V homozygous genotype: 57.1% vs.
58.8%; non-M694V homozygous genotypes: 10.0% vs.
25.9%; Mantel-Haenszel test: ; data notPp .493
shown), or when the group of patients carrying at least
one 2 allele was compared with that of patients who
did not carry any 2 allele (data not shown).
Sex-Related Prevalence of Renal Amyloidosis
The overall male:female ratio in our cohort of patients
with FMF was 1.40 (80:57). The male:female ratio in
patients with renal amyloidosis was higher than that of
patients without renal amyloidosis (35:12 [2.92] vs. 45:
45 [1.00], ; table 2). This difference persistedPp .006
when adjusted on the MEFV genotype (fig. 1b; Pp
) and was particularly marked in patients who did.0202
not carry the M694V homozygous genotype; indeed, in
this latter group, 34% (18/53) of male patients presented
with renal amyloidosis, compared with only 11.6% (5/
43) of female patients.
Age at Onset, Duration of the Disease at Study Entry,
and Renal Amyloidosis
The duration of the disease among patients with renal
amyloidosis ( ) was similar to that among patientsnp 44
without renal amyloidosis ( ; andnp 85 18.7 10.3
years, respectively; ; table 2).How-16.3 12.8 Pp .142
ever, the age at onset of the disease was significantly lower
in patients with renal amyloidosis than in those without
this complication ( vs. ;9.1 10.5 12.1 10.5 Pp
; table 2). This association actually reflects the un-.022
balanced distribution of MEFV genotypes between the
two groups, since the age at onset is lower in patients
with theM694V homozygous genotype than in thosewho
carried another MEFV genotype ( and5.8 5.3 7.9
vs. and , in patients with9.7 13.4 11.0 10.8 11.6
and without renal amyloidosis, respectively; ).Pp .016
Multivariate Analysis
The odds ratios (ORs) presented in table 3 were esti-
mated from the stepwise logistic model that takes into
account the duration of the disease. In our population
sample, theM694Vhomozygous genotypewas associated
with a sevenfold increased risk for renal amyloidosis,
compared with otherMEFV genotypes ( ; 95%ORp 6.8
). The results obtained with regard toCIp 2.7–17.8
SAA1 genotype showed that the patients who carried the
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Table 2
Clinical Characteristics of the Patients, According to the Presence or Absence of Renal Amyloidosis
(Univariate Analysis)
PATIENTS
SEX (NO. [%] OF PATIENTS)
AGE AT ONSET
(YEARS, MEAN  SD) P
DURATION OF DISEASE
(YEARS, MEAN  SD) PMale Female P
With RA 35 (74.5) 12 (25.5) 9.1  10.5 18.7  10.3
Without RA 45 (50.0) 45 (50.0) 12.1  10.5 16.3 12.8
Overall .006 .022 .142
NOTE.—RA p renal amyloidosis.
Table 3
Factors Associated With Renal Amyloidosis (Multivariate Logistic
Regression Analysis)
Variable
Percentage
(No./Total)
of Patients with RA
Adjusted ORsa
(95% CI) P
MEFV genotype:
M694V/M694V 58.5 (24/41) 6.8 (2.7–17.8) .0001
Otherb 24.0 (23/96) 1
Sex:
Male 43.7 (35/80) 4.0 (1.5–10.8) .003
Femaleb 21.1 (12/57) 1
SAA1 genotype:
a/a 59.5 (22/37) 6.9 (2.5–19.0) .001
Otherb 25.0 (25/100) 1
NOTE.—RA p renal amyloidosis.
a ORs were also adjusted on duration of the disease.
b Reference category.
SAA1a homozygous genotype had a sevenfold increased
risk for renal amyloidosis, compared with those who car-
ried another SAA1 genotype ( ; 95%ORp 6.9 CIp
). The risk for men with FMF to develop renal2.5–19.0
amyloidosis was found to be fourfold higher than that
for women with FMF ( ; 95% ).ORp 4.0 CIp 1.5–10.8
We observed no evidence of interaction between the pa-
tient’s sex and the genotype at the SAA1 locus. This find-
ing therefore suggests that genetic variations at the SAA1
locus predisposes to renal amyloidosis in a manner that
is independent of the patient’s sex.
Discussion
Variability in clinical expression of the disease phenotype
is a common feature of many genetic disorders. In theory,
this phenomenon may result from allelic heterogeneity
and/or from the influence of environmental or modifying
genetic factors. Although identification of such modifier
genes represents one of the major current challenges in
human genetics, these complex studies are usually ham-
pered by the potentially large number of independent
genetic and environmental factors that may contribute
to the disease phenotype, thereby making correlations
between the phenotype and candidate modifier factors
difficult to establish. In the case of FMF, the variable
risk for patients carrying the same MEFV mutations to
develop renal amyloidosis strongly suggests a role for
other genetic and/or environmental factors. In the pre-
sent study, we have selected and tested several candidate
modifier factors and identified two MEFV-independent
factors of genetic origin, SAA1 and sex, that indeed af-
fect this risk by acting independently of each other.
In an attempt to overcome the well-known difficulties
in identifying modifying genetic factors, we focused our
efforts on the investigation of a large population sample
of Armenian patients living in Armenia. Indeed, in this
relatively homogeneous population, we expected the pa-
tients not only to share a common genetic background
but also to have been exposed to similar environmental
factors—two conditions that would facilitate the iso-
lation of major modifying factors of genetic origin. The
MEFV genotype was also taken into account in the
interpretation of the data. Previous genotype-phenotype
correlation studies indeed showed an association be-
tween the M694V homozygous genotype at the MEFV
locus and the risk of occurrence of renal amyloidosis in
patients with FMF (Cazeneuve et al. 1999; Shohat et
al. 1999). As expected, a similar association was found
in the present study. Therefore, to overcome the con-
founding effect of the M694V homozygous genotype
on the interpretation of the data, the comparisons be-
tween patients with and without renal amyloidosis were
adjusted on the MEFV genotype.
The mean duration of the disease in patients with
renal amyloidosis was found to be similar to that of
patients without renal amyloidosis, ruling out a bias
related to follow-up duration. However, the age at onset
of the disease in our cohort of patients was lower in
individuals with the M694V homozygous genotype
than in those with another MEFV genotype, an obser-
vation that is similar to that recorded in patients of
Sephardic Jewish extraction who have FMF (Dewalle
et al. 1998). The age at onset was also lower in patients
with renal amyloidosis than in those without this com-
plication. These last two observations are actually
linked and reflect the unbalanced distribution ofMEFV
genotypes between the two groups.
Candidate modifiers of genetic origin in FMF-associ-
ated renal amyloidosis would include factors that par-
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ticipate in amyloid deposits. We therefore investigated
the genes encoding the major acute-phase serum amyloid
A1 (SAA1) andA2 (SAA2) proteins, which are precursors
of the amyloid A (AA) proteins present in the amyloid
fibrils found in AA secondary amyloidosis. The present
study identified a significant and important relationship
between the SAA1 genotype and the risk for patientswith
FMF to develop renal amyloidosis. The SAA1a/a ge-
notype was indeed associated with a sevenfold increased
risk for renal amyloidosis, compared with other SAA1
genotypes, thereby demonstrating the pivotal contribu-
tion of the SAA1 locus in the occurrence of this major
complication. This result relates to the data recorded in
patients with rheumatic arthritis or juvenile chronic ar-
thritis, two non-Mendelian disorders of unknown etiol-
ogy characterized by a chronic inflammatory syndrome:
in these disorders, the risk of developing secondary amy-
loidosis was shown to be higher in patients with the
SAA1a/a genotype than in those carrying another SAA1
genotype (Booth et al. 1998a). Our study also revealed
that the presence of only one SAA1a allele did not confer
a high susceptibility to renal amyloidosis, thereby indi-
cating that, in patients with FMF, the predisposition to
this particular complication linked to the SAA1a allele
may be considered to be a recessive trait. In addition, it
is striking to note that the association of the SAA1a/a
genotype with renal amyloidosis, which was present
whatever the MEFV genotype, was extremely marked in
M694V-homozygous patients. Renal amyloidosis was in-
deed present in all the patients ( [100%]) whonp 11
were homozygous for both the SAA1a and M694V al-
leles. Because no patient without renal amyloidosis car-
ried these genotypes at the SAA1 and MEFV loci, it was
impossible to calculate the OR associated with the in-
teraction between theses two factors, although this in-
teraction is likely to be high. Altogether, these data raise
the question of the mechanism(s) by which the SAA1a/
a genotype predisposes to secondary amyloidosis. Al-
though the relationship between this genotype and the
occurrence of renal amyloidosis is not straightforward,
at least three hypotheses can be advanced. First, the SAA
plasma level might be higher in patients carrying the
SAA1a/a genotype than in those carrying another SAA1
genotype. However, in the Japanese population, in which
the risk for patients with rheumatic arthritis or juvenile
chronic arthritis to develop secondary amyloidosis has
been shown to be associated with the SAA1g/g genotype
(Baba et al. 1995;Moriguchi et al. 1999), the SAAplasma
level of healthy subjects carrying this genotype was lower
than that of control individuals with another SAA1 ge-
notype (Yamada et al. 1999). This observation therefore
does not support the hypothesis that the risk for second-
ary amyloidosis is directly related to the plasma concen-
tration of SAA. Second, because macrophages are
thought to play a key role in the formation of amyloid
A proteins and amyloid fibrils from the SAA protein
(Kluve-Beckerman et al. 1999), it is tempting to speculate
that the high susceptibility of the SAA1a/a genotype to
secondary amyloidosis may result from a greater mac-
rophage uptake of the SAA1a isoform, compared with
that of b and g isoforms. Consistent with this hypothesis,
it has been shown that the amyloidogenic SAA isoform
in mice, SAA1.1, displays an increased plasma clearance,
compared with nonamyloidogenic SAA proteins (Meek
et al. 1986; Kluve-Beckerman et al. 1997), and specifi-
cally binds RAGE—a multiligand immunoglobulin su-
perfamily cell surface molecule expressed in macro-
phages—with nanomolar affinity (Kisilevsky 2000; Yan
et al. 2000). One also cannot exclude the possibility that
the human SAA1a isoform may undergo a macrophage
processing different from that of b and g isoforms. Last,
theaAA1 isoformmay also have a high intrinsic potential
to promote fibrillogenesis, compared with that of b and
g AA1 isoforms. Further studies focused on the pro-
cessing of each SAA1 isoform in macrophages and on
the assessment of their respective amyloidogenic poten-
tialities might be helpful in deciphering the molecular
basis of the greater susceptibility for SAA1a homozygous
patients to develop renal amyloidosis. Despite the struc-
tural and functional similarities between SAA1 and
SAA2, the SAA2 locus did not significantly affect the risk
of occurrence of renal amyloidosis in our population
sample. This result may, however, be related to the mi-
nority representation of AA2 in amyloid deposits (Liep-
nieks et al. 1995).
We also considered the APOE genotype to be a good
candidate modifier factor for renal amyloidosis in FMF.
Indeed, although the mechanisms by which AA proteins
accumulate in amyloidosis are not fully understood, sev-
eral lines of evidence indicate the role of apolipoprotein
E (ApoE) in this phenomenon: the ApoE protein has been
identified in the FMF-associated amyloid deposits found
in vivo (Wisniewski and Frangione 1992); furthermore,
in vitro incubation of native AA peptides with the ApoE
protein resulted in a higher degree of polymerization of
amyloid A peptide, compared with control incubations
performed without ApoE (Castan˜o et al. 1995). In ad-
dition, the APOE4 allele has clearly been associated
with an increased risk of developing Alzheimer disease
(Saunders et al. 1993), a disorder characterized by brain
deposition of the b-amyloid protein. The role of the
APOE4 allele in promoting fibrillogenesis of the amy-
loid Ab peptide is also supported by in vitro studies that
showed that ApoE, and especially the ApoE4 isoform,
accelerate the spontaneous fibrillogenesis of amyloid b
peptide (Wisniewski et al. 1994). However, in this study,
we did not find any evidence supporting the hypothesis
that, in patients with FMF, allelic variations at theAPOE
locus modify the risk of occurrence of renal amyloidosis.
Even though the number of our patients carrying the 4
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allele is relatively small, a major effect of this allele should
have been identified, if it existed. This result, however,
does not rule out the possibility that the different ApoE
isoforms may have slight differential effects on the fi-
brillogenesis of AA proteins.
It is usually found that FMF is more frequent in men
than in women (Wolff 1994). The present study showed
that men and women were equally represented among
patients without amyloidosis (45 men and 45 women),
whereas the male:female ratio was clearly unbalanced in
patients with amyloidosis (35 men and 12 women). Men
with FMF had a fourfold increased risk for renal amy-
loidosis, compared with women with FMF, the difference
being particularly marked in patients who did not carry
the M694V homozygous genotype (34.0% vs. 11.6%).
The mechanism by which the patient’s sex can modify
the risk of amyloidosis is unclear. Although sex steroid
hormones are known to influence the concentration of
several acute-phase proteins (Whicher 1983),whether the
inflammatory syndrome in patients with FMF is more
important in men than in women has not yet been
documented.
In most Mendelian disorders that are inherited in a
simple fashion, it is now well established that individuals
with identical mutations in the disease-causing gene may
differ clinically. These observations, which reflect the ex-
istence of additional environmental factors or genes that
contribute to the disease phenotypes, support the concept
that, for these Mendelian disorders, the phenotypes are,
in fact, complex traits (reviewed by Romeo and Mc-
Kusick 1994; Dipple and McCabe 2000). The modifier
factors of genetic origin accounting for this phenotypic
diversity can be classified into three categories, with al-
lelic variations involving the disease gene itself, a locus
genetically linked to the disease gene, or a disease-
gene–independent locus (Feingold 2000). A relatively
limited but increasing number of observations that fall
into the two first categories have been reported in human
populations. This is, for instance, the case for fatal fa-
milial insomnia and familial Creutzfeldt-Jakob disease,
two neurological disorders linked to the same mutation
of the prion-protein gene but associated with different
apparently benign polymorphisms in the same gene
(Goldfarb et al. 1992), whereas the disease severity in
spinal muscular atrophy, a recessive disorder due to ab-
normalities in the SMN1 gene, is associated with dele-
tions of the H4F5 gene, which maps a few kilobases
upstream of SMN1 (Scharf et al. 1998). In contrast with
these situations, the present study identifies modifier fac-
tors of genetic origin that are not linked to the disease-
causing gene. To our knowledge, there are very few prec-
edents for this situation in the human species, in which
such modifiers cannot be easily identified, although their
action is often suspected. One analogue is the familial
hypertrophic cardiomyopathy due to mutations in the b-
MHC gene, in which severity is associated with an in-
sertion/deletion polymorphism in the ACE gene (Tesson
et al. 1997). In this study, we have identified a key role
for the SAA1 locus in conferring genetic susceptibility to
renal amyloidosis, the most severe complication of FMF,
which can be prevented by lifelong administration of col-
chicine. Male patients are also clearly more exposed to
the risk of developing renal amyloidosis, compared with
female patients with FMF. In light of these results, it
would certainly be of particular interest to investigate
other FMF population samples, following a similar can-
didate-gene approach. Taken together, the identification
of these two MEFV-independent modifying genetic fac-
tors for FMF provides insights into the pathophysiology
of the FMF-associated secondary amyloidosis A and
raises the possibility that determination of the SAA1 ge-
notypemight be useful in assessing the patient’s prognosis
with respect to renal function.
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